VAXIL BIO LTD.

Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner. Vaxil’s first test of itsVaxHitplatform is itsImmucin; lead immunotherapy product. After completion of a successful Phase-I/II in 15 multiple myeloma cancer patients, Vaxil’s Immucin was granted Orphan Drug Status by the FDA and EMA for that indication. Vaxil’s development is supported by Six specialized immunology scientists, Four of whom received PhD’s at the Weizmann Institute, Israel’s top scientific university. The Company has developed a robust scientific IP. Research & clinical trial data have been published in high-impact-factor medical journals, all patients treated at top medical centers. VAXIL TRIALS CONDUCTED AT TOP MEDICAL SITES AND RESEARCH PUBLISHED IN THE BEST MEDICAL JOURNALS.